166,500 Shares in Zura Bio Limited $ZURA Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP acquired a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 166,500 shares of the company’s stock, valued at approximately $872,000. Zura Bio accounts for 0.7% of Seven Fleet Capital Management LP’s portfolio, making the stock its 28th biggest position. Seven Fleet Capital Management LP owned approximately 0.26% of Zura Bio as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Zura Bio in the fourth quarter valued at approximately $348,000. Suvretta Capital Management LLC lifted its holdings in Zura Bio by 1.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after buying an additional 94,110 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Zura Bio during the fourth quarter valued at $192,000. Millennium Management LLC boosted its stake in shares of Zura Bio by 75.1% in the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock valued at $5,411,000 after purchasing an additional 442,980 shares during the last quarter. Finally, 683 Capital Management LLC bought a new position in Zura Bio in the fourth quarter valued at approximately $1,358,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZURA. Oppenheimer reduced their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Finally, Chardan Capital increased their target price on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Stock Up 3.6%

Shares of NASDAQ:ZURA opened at $3.75 on Friday. The stock has a market cap of $355.80 million, a PE ratio of -3.44 and a beta of 0.03. The business has a 50 day moving average of $4.62 and a 200-day moving average of $5.23. Zura Bio Limited has a 12-month low of $1.00 and a 12-month high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Equities research analysts expect that Zura Bio Limited will post -0.76 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.